As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Harnessing the power of microglia
to transform treatments for
neurodegenerative diseases
Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016
Broadening the reach and
impact of precision medicine
to more people with cancer
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)
Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)
Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020
